Although no clinically approved drugs currently exist that directly target ceramide signaling in gliomas, several ASAH1 inhibitors—such as carmofur, N-oleoylethanolamine, and ARN14988—have demonstrated efficacy in vitro across multiple glioma cell lines, including U87 and patient-derived cells. Here, ASAH1 is linked to central nervous system cancer.